SCHEDULE: Adage Capital Management Discloses 8.43% Stake in Cabaletta Bio

Adage Capital Management, L.P. has reported a beneficial ownership of 8.43% in Cabaletta Bio, Inc., including shares issuable upon warrant exercise.

Summary

• Adage Capital Management, L.P. (ACM), through its affiliate Adage Capital Partners, L.P. (ACP), has filed a Schedule 13G, reporting beneficial ownership of 14,174,758 shares of Cabaletta Bio, Inc. common stock.
• This holding represents 8.43% of the company's outstanding common stock as of May 7, 2026.
• The reported shares include 5,000,000 shares of common stock issuable upon the exercise of warrants held by ACP.
• Robert Atchinson and Phillip Gross, as managing members of entities related to ACM and ACP, are also listed as reporting persons.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake by an investment manager, with no immediate red flags but also no strong buy signals.

Positives

• Significant stake taken by a known investment manager (Adage Capital Management) suggests confidence in the company's future prospects.
• The stake includes potential upside from exercisable warrants, indicating a belief in the stock's ability to appreciate.
• The filing confirms the shares are held in the ordinary course of business, implying a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not provide specific details on the investment strategy or the rationale behind acquiring this stake.
• The reporting persons have shared voting and dispositive power, which could indicate a lack of complete unilateral control over the shares.

Risks

• The filing does not explicitly mention any risks, as it is a Schedule 13G reporting beneficial ownership.
• Potential for future changes in beneficial ownership, which could impact stock price volatility.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Cabaletta Bio. It is a disclosure of beneficial ownership by Adage Capital Management.

Management Comments

• "The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stake building by institutional investors, as indicated by this Schedule 13G filing, can often precede or coincide with positive developments or strategic shifts within a biotechnology company. However, the nature of this filing is purely a disclosure of ownership, not an endorsement or strategic commentary from the company itself.

Comparison to Industry Standards

• Schedule 13G filings are standard disclosures for beneficial ownership exceeding 5% by passive investors.
• The 8.43% stake is a substantial holding for a passive investor, indicating a significant conviction in Cabaletta Bio's potential.
• The inclusion of warrants in the beneficial ownership calculation is a common practice for investment managers to reflect potential future share acquisition.

Stakeholder Impact

• Shareholders may view the increased institutional ownership positively, potentially signaling increased confidence in the company's long-term value.
• The reporting persons (Adage Capital Management and its affiliates) are now significant stakeholders, aligning their interests with other shareholders.

Next Steps

• Monitor future filings from Adage Capital Management for any changes in their stake.
• Observe Cabaletta Bio's operational and clinical developments for potential catalysts that may have influenced Adage's investment.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While the significant stake by Adage Capital Management is a positive indicator of institutional confidence, the filing is a passive ownership disclosure and does not provide new operational or financial performance data for Cabaletta Bio. Further analysis of the company's fundamentals and clinical progress is required for a stronger conviction.

Keywords

Cabaletta Bio, Adage Capital Management, Schedule 13G, Beneficial Ownership, Warrants, Investment Management, Securities Exchange Act